Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that blocks signals from the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway, which coordinates cell proliferation and survival central to the development of vascular anomalies.1,2 Oral sirolimus is widely used to treat varied vascular anomalies and is associated with diverse adverse events (AEs), including leukopenia, gastrointestinal symptoms, infectious complications, and dyslipidemia.1,2 Limited data exist regarding dermatologic AEs in populations with vascular anomalies.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Grenier P, McCormack L, Alshamekh SA, et al. Mucocutaneous Adverse Events Associated With Oral Sirolimus for the Treatment of Vascular Anomalies. JAMA Dermatol. 2021;157(2):233–235. doi:10.1001/jamadermatol.2020.5180
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.